Dr. Ming Wang is Founder, President and CEO of Phanes Therapeutics, Inc. based in San Diego. The company focuses on drug discovery and development to treat cancer and metabolic complications. Ming was formerly Vice President and Disease Area Leader of Diabetes/Metabolism in Janssen, the pharmaceutical sector of Johnson & Johnson, with global responsibility for the […]
Dr. Hui Zou is an experienced and accomplished oncologist in both academia of biological research and industry of drug development. Before joining the industry, Hui was a tenured Associate Professor of the Department of Molecular Biology at UT Southwestern Medical Center. He was awarded American Cancer Society Research Scholar and Kenneth G. and Elaine A. […]
Dr. Rita Laeufle brings more than 18 years of experience in drug development in oncology and Immunotherapy, most recently serving as CMO at Imugene Biotech, Australia where she is responsible for their oncolytic virus and B-cell vaccine program. During her previous position at Oncolytics, she developed immunotherapy combination studies with the oncolytic virus pelareorep and […]
Dr. Satya (Nanu) Das is a medical oncologist with a background in gastrointestinal (GI) cancer, neuroendocrine cancer and Phase 1 trials. Before joining industry, Nanu was an Assistant Professor of Medicine at Vanderbilt University Medical Center, where he led the Neuroendocrine Tumor (NET) program and co-led the Upper-GI Malignancies program. He was the recipient of […]
Chelsea Johnson, RN, joined Phanes Therapeutics as Senior Director, Clinical Science and Operations. Ms. Johnson supports clinical development and serves as the lead for the clinical operations team for advancing Phanes clinical studies and managing relationships with the clinical sites. Ms. Johnson has over 15 years of experience in clinical development and clinical operations, from […]
Dirk Arnold completed his MD degree at the Universities of Ulm and Berlin in Germany, and he undertook specialist training at Charité, Humboldt University in Berlin. Subsequently, he trained as a medical oncologist and specialist in palliative care at the Martin Luther University Halle-Wittenberg in Halle, Germany. In 2009, he qualified with a clinical PhD […]
Professor Tony Mok, BBS BMSc, MD, FRCP(C), FRCP(Edin), FRCP(Lond), FHKCP, FHKAM(Medicine), FASCO, Member of ASHK Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada for seven years, […]
Dr. Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After […]
Professor Lu is a leading clinician-scientist in the field of lung cancer. He is Professor and Chief of Shanghai Lung Cancer Center at Shanghai Chest Hospital, Shanghai Jiao Tong University. He holds an M.D. degree and a Ph.D. degree, and trained at MD Anderson Cancer Center in the United States and worked as a Visiting […]
Dr. Kohei Shitara is the Director of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. He received his medical degree from Tohoku University School of Medicine in 2002. Dr Shitara is an active member of ASCO and ESMO. He is working as one of the ESMO faculty member for Gastrointestinal […]
